ORAGENICS, INC. Operating Lease Cost
ORAGENICS, INC. (OGEN) reported Operating Lease Cost of $191.36 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2024-03-29
- ORAGENICS, INC. operating lease, cost for the quarter ending 2023-12-31 was $16.92K, a 85.30% decline year-over-year.
- ORAGENICS, INC. operating lease, cost for the quarter ending 2023-09-30 was $58.34K.
- ORAGENICS, INC. operating lease, cost for the quarter ending 2023-06-30 was $58.34K, a 2.12% increase year-over-year.
- ORAGENICS, INC. operating lease, cost for the quarter ending 2023-03-31 was $57.76K, a 1.10% increase year-over-year.
- ORAGENICS, INC. operating lease, cost for fiscal 2023 was $191.36K, a 16.55% decline from fiscal 2022.
- ORAGENICS, INC. operating lease, cost for fiscal 2022 was $229.31K, a 0.47% increase from fiscal 2021.
- ORAGENICS, INC. operating lease, cost for fiscal 2021 was $228.23K, a 0.95% increase from fiscal 2020.
- ORAGENICS, INC. operating lease, cost for fiscal 2020 was $226.09K, a 5.47% increase from fiscal 2019.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $16.92K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $75.26K derived: sum of 2 quarters · filed 2024-03-29 | $133.60K derived: sum of 3 quarters · filed 2024-03-29 | $191.36K 10-K · filed 2024-03-29 | |
| 2023-09-30 | $58.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $116.69K derived: sum of 2 quarters · filed 2023-11-09 | $174.44K 10-Q · filed 2023-11-09 | $289.50K derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-06-30 | $58.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $116.10K 10-Q · filed 2023-08-11 | $231.15K derived: sum of 3 quarters · filed 2024-03-29 | $231.15K derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-03-31 | $57.76K 10-Q · filed 2023-05-12 | $172.81K derived: sum of 2 quarters · filed 2024-03-29 | $172.81K derived: sum of 3 quarters · filed 2024-03-29 | $229.94K derived: sum of 4 quarters · filed 2024-03-29 | |
| 2022-12-31 | $115.05K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $115.05K derived: sum of 2 quarters · filed 2024-03-29 | $172.18K derived: sum of 3 quarters · filed 2024-03-29 | $229.31K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $57.13K derived: sum of 2 quarters · filed 2023-11-09 | $114.26K 10-Q · filed 2023-11-09 | $171.39K 10-Q · filed 2022-11-14 | $171.45K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $57.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $114.26K 10-Q · filed 2023-08-11 | $171.45K derived: sum of 3 quarters · filed 2023-08-11 | $228.49K derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $57.13K 10-Q · filed 2023-05-12 | $114.32K derived: sum of 2 quarters · filed 2023-05-12 | $171.36K derived: sum of 3 quarters · filed 2023-05-12 | $228.40K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $57.19K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-04-17 | $114.23K derived: sum of 2 quarters · filed 2023-04-17 | $171.27K derived: sum of 3 quarters · filed 2023-04-17 | $228.23K 10-K · filed 2023-04-17 | |
| 2021-09-30 | $57.04K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2023-04-14 | $114.08K derived: sum of 2 quarters · filed 2023-04-14 | $171.04K 10-Q/A · filed 2023-04-14 | $228.00K derived: sum of 4 quarters · filed 2023-04-14 | |
| 2021-06-30 | $57.04K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2023-04-14 | $114.00K 10-Q/A · filed 2023-04-14 | $170.97K derived: sum of 3 quarters · filed 2023-04-14 | $227.93K derived: sum of 4 quarters · filed 2023-04-14 | |
| 2021-03-31 | $56.96K 10-Q/A · filed 2023-04-14 | $113.93K derived: sum of 2 quarters · filed 2023-04-14 | $170.89K derived: sum of 3 quarters · filed 2023-04-14 | $227.86K derived: sum of 4 quarters · filed 2023-04-14 | |
| 2020-12-31 | $56.96K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-29 | $113.93K derived: sum of 2 quarters · filed 2022-07-29 | $170.89K derived: sum of 3 quarters · filed 2022-07-29 | $226.09K 10-K/A · filed 2022-07-29 | |
| 2020-09-30 | $56.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $113.93K derived: sum of 2 quarters · filed 2021-11-15 | $169.13K 10-Q · filed 2021-11-15 | $225.93K derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $56.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $112.16K 10-Q · filed 2021-08-16 | $168.97K derived: sum of 3 quarters · filed 2021-08-16 | $227.20K derived: sum of 4 quarters · filed 2021-08-16 | |
| 2020-03-31 | $55.20K 10-Q · filed 2021-05-03 | $112.00K derived: sum of 2 quarters · filed 2021-05-03 | $170.24K derived: sum of 3 quarters · filed 2021-05-03 | $220.11K derived: sum of 4 quarters · filed 2021-05-03 | |
| 2019-12-31 | $56.80K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $115.04K derived: sum of 2 quarters · filed 2021-03-01 | $164.91K derived: sum of 3 quarters · filed 2021-03-01 | $214.36K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $58.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $108.11K derived: sum of 2 quarters · filed 2019-11-14 | $157.56K 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | $49.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $99.32K 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $49.45K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |